stars 1 stars 2 stars 3

Cell2B is a biotechnology company dedicated to the development of a new line of healthcare therapies to prevent and treat organ rejection in patients undergoing organ or tissue transplants. Cell-based therapy has the potential to impact the life of more than 175,000 patients per year in Europe. Cell2B focuses on the development and processing of cell-based therapies for treating patients and improving their quality of life. Cell2B, incorporated in 2011, also focuses on research and development (R&D) of new cellular therapies for clinical use and offers complementary activities to R&D in the cell therapy space. R&D in cellular therapy is crucial in Cell2B’s vision, it enables to improve therapeutic solutions for the patients.

Cell2B Questions

The Cell2B annual revenue was $5 million in 2026.

The NAICS codes for Cell2B are [54171, 541711, 541, 5417, 54].

The SIC codes for Cell2B are [28, 283, 80].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users